Literature DB >> 2975806

Antidepressant-induced weight gain: a comparison study of four medications.

M H Fernstrom1, D J Kupfer.   

Abstract

Body weight change was monitored in 73 hospitalized depressed patients treated with one of four antidepressants for 1 month. After a 2-week medication-free period, patients were randomly assigned to treatment with amitriptyline, nortriptyline, desipramine, or zimelidine. By the end of 1 month, treatment with all three tricyclic compounds promoted weight gain, with the greatest increase observed during amitriptyline treatment; less weight was gained by patients treated with nortriptyline and desipramine. In contrast, most patients treated with zimelidine showed no weight gain and, in many cases, demonstrated weight loss. Weight change during treatment was not associated with age, sex, severity of depression, obesity, weight loss during depression, or clinical response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975806     DOI: 10.1016/0165-1781(88)90120-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  Desvenlafaxine and weight change in major depressive disorder.

Authors:  Karen A Tourian; Claire Leurent; Jay Graepel; Philip T Ninan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 4.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 5.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

6.  The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat.

Authors:  Neil E Paterson; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2008-04-29       Impact factor: 4.530

7.  Tools for Successful Weight Management in Primary Care.

Authors:  Christy Boling Turer
Journal:  Am J Med Sci       Date:  2015-12       Impact factor: 2.378

8.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Authors:  Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 9.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

Review 10.  Medications that cause weight gain and alternatives in Canada: a narrative review.

Authors:  Sean Wharton; Lilian Raiber; Kristin J Serodio; Jasmine Lee; Rebecca Ag Christensen
Journal:  Diabetes Metab Syndr Obes       Date:  2018-08-21       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.